Autophagy in Pituitary Neuroendocrine Tumors (PitNETs): Molecular Mechanisms, Secretory Homeostasis, Therapeutic Resistance, and Translational Perspectives
- 1Anatomic Pathology Unit, Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”, University of Messina, 98125 Messina, Italy
- 2PhD Program in Translational Molecular Medicine and Surgery, Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy
- 3Department of Medical and Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, Anatomic Pathology, University of Catania, 95123 Catania, Italy
Abstract
Pituitary neuroendocrine tumors (PitNETs) are usually indolent but may show invasive growth, recurrence, hormonal hypersecretion, and treatment resistance. Autophagy intersects with nutrient sensing, lysosomal homeostasis, mitochondrial quality control, and secretory-granule turnover, but its biological effects in PitNETs are context-dependent. This narrative review synthesizes PitNET-specific and mechanistically relevant evidence on macroautophagy, mitophagy, crinophagy, non-coding RNA and epigenetic regulation, treatment resistance, and pharmacological modulation, emphasizing the distinction between static autophagy markers and dynamic autophagic flux. Evidence is interpreted across human tissue, primary human cells, pituitary tumor cell lines, animal models, and clinical observations, while preserving clear separation between human observations and mechanistic evidence derived from experimental models. Across experimental systems, autophagy activation is associated with antitumor effects in selected settings, whereas completed basal flux may support stress adaptation and late-stage or selective-autophagy inhibition may enhance cytotoxicity. Biological outcome therefore depends on tumor lineage, treatment, the pathway stage affected, and whether flux is completed. Recent studies extend this framework to selective mitophagy, ncRNA/exosomal resistance networks, epitranscriptomic regulation, somatostatin-analogue resistance, and tumor-microenvironmental signaling. Clinical translation remains limited, and no autophagy-modulating strategy is validated for routine PitNET management. Future studies should integrate dynamic flux measurements, lineage-specific biomarkers, pharmacodynamic target engagement, and prospective clinical endpoints.
Related
- Targeting the NLRP3 inflammasome in rheumatoid arthritis fibroblast-like synoviocytes: pathogenic mechanisms, therapeutic strategies, and translational perspectives
- Hydrogel-based delivery of extracellular vesicles for skin wound healing: design strategies, therapeutic mechanisms, and translational perspectives
- Inflammation and wound healing: a comprehensive overview of mechanisms, therapeutic strategies, and translational perspectives
- Editorial: Unveiling the complexity of neuroendocrine neoplasms: biomarkers, classification, and translational perspectives
- Low-energy extracorporeal shock wave therapy for interstitial cystitis/bladder pain syndrome: mechanisms, evidence, and translational perspectives—a narrative review
BibTeX
@article{rizzuto2026autophagy,
title = {{Autophagy in Pituitary Neuroendocrine Tumors (PitNETs): Molecular Mechanisms, Secretory Homeostasis, Therapeutic Resistance, and Translational Perspectives}},
author = {Ida Rizzuto and Ludovica Pepe and Giuseppe Broggi and Rosario Caltabiano and Vincenzo Fiorentino and Antonio Ieni},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27209195},
url = {https://www.mdpi.com/1422-0067/27/20/9195},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Autophagy in Pituitary Neuroendocrine Tumors (PitNETs): Molecular Mechanisms, Secretory Homeostasis, Therapeutic Resistance, and Translational Perspectives
AU - Ida Rizzuto
AU - Ludovica Pepe
AU - Giuseppe Broggi
AU - Rosario Caltabiano
AU - Vincenzo Fiorentino
AU - Antonio Ieni
PY - 2026
DA - 2026/10/01
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27209195
UR - https://www.mdpi.com/1422-0067/27/20/9195
AB - Pituitary neuroendocrine tumors (PitNETs) are usually indolent but may show invasive growth, recurrence, hormonal hypersecretion, and treatment resistance. Autophagy intersects with nutrient sensing, lysosomal homeostasis, mitochondrial quality control, and secretory-granule turnover, but its biological effects in PitNETs are context-dependent. This narrative review synthesizes PitNET-specific and mechanistically relevant evidence on macroautophagy, mitophagy, crinophagy, non-coding RNA and epigenetic regulation, treatment resistance, and pharmacological modulation, emphasizing the distinction between static autophagy markers and dynamic autophagic flux. Evidence is interpreted across human tissue, primary human cells, pituitary tumor cell lines, animal models, and clinical observations, while preserving clear separation between human observations and mechanistic evidence derived from experimental models. Across experimental systems, autophagy activation is associated with antitumor effects in selected settings, whereas completed basal flux may support stress adaptation and late-stage or selective-autophagy inhibition may enhance cytotoxicity. Biological outcome therefore depends on tumor lineage, treatment, the pathway stage affected, and whether flux is completed. Recent studies extend this framework to selective mitophagy, ncRNA/exosomal resistance networks, epitranscriptomic regulation, somatostatin-analogue resistance, and tumor-microenvironmental signaling. Clinical translation remains limited, and no autophagy-modulating strategy is validated for routine PitNET management. Future studies should integrate dynamic flux measurements, lineage-specific biomarkers, pharmacodynamic target engagement, and prospective clinical endpoints.
SN - 1422-0067
ER -